WCN26-4471 CXCL13 Expression in the Lymph Node and Kidney of a Patient with Idiopathic Multicentric Castleman Disease with TAFRO Syndrome

Key Points

• This study aims to evaluate the expression of CXCL13 and the efficacy of telitacicept in patients with idiopathic multicentric Castleman disease.
• Analyzed CXCL13 expression in lymph nodes and kidneys using patient samples.
• Administered low-to medium-dose telitacicept along with conventional therapy.
• Monitored treatment efficacy and safety outcomes.
• Telitacicept showed good onset efficacy in treating IgA patients.
• The combination therapy was safe with no significant adverse events reported.